drugset

drugset / Trial / NCT00258960

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

NCT00258960 ↗

Phase 2 Completed 49 enrolled Spanish Breast Cancer Research Group Schering-Plough · collab

NaSingle-groupOpen-labelTreatment

Summary

Eligible patients must receive Caelyx plus Cyclophosphamide plus Herceptin for 6 cycles that will be administered every 4 weeks.

Timeline

Start: 2006-02-15
Primary completion: 2008-07
Completion: 2009-07-14

Publications

Results Martin M, Sanchez-Rovira P, Munoz M, Baena-Canada JM, Mel JR, Margeli M, Ramos M, Martinez E, Garcia-Saenz JA, Casado A, Jaen AM, Gonzalez-Farre X, Escudero MJ, Rodriguez-Martin C, Carrasco E; GEICAM. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. Ann Oncol. 2011 Dec;22(12):2591-2596. doi: 10.1093/annonc/mdr024. Epub 2011 Mar 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	600 mg/m2	—
Subject	Doxorubicin	Other / unclassified	50 mg/m2	—
Subject	Trastuzumab	Monoclonal antibody	2 mg/kg	—

Indications